Marta Maddalo1, Pierluigi Bonomo2, Liliana Belgioia3, Almalina Bacigalupo3, Vittorio Donato4, Daniela Alterio5, Ester Orlandi6, Angela Argenone7, Anna Merlotti8, Daniela Musio9, Marianna Trignani10, Stefano Ursino11, Stefano Arcangeli4, Carlo Furlan12, Mattia Falchetto Osti13. 1. Radiation Oncology Department, Università di Brescia-Istituto del Radio "O. Alberti" Spedali Civili di Brescia, Brescia, Italy. 2. Radiation Oncology Department, Azienda Ospedaliero-Universitaria Careggi, Largo G. Alessandro Brambilla, 3, 50134, Firenze, Italy. bonomopierlu@gmail.com. 3. Radiation Oncology Department, Ospedale Policlinico San Martino-Università di Genova, Genova, Italy. 4. Radiation Oncology Department, Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy. 5. Radiation Oncology Department, Istituto Europeo di Oncologia, Milano, Italy. 6. Radiation Oncology Department, Fondazione IRCCS-Istituto Nazionale dei Tumori, Milano, Italy. 7. Radiation Oncology Department, Istituto Nazionale Tumori-IRCSS-Fondazione G. Pascale, Napoli, Italy. 8. Radiation Oncology Department, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy. 9. Radiation Oncology Department, Ospedale Policlinico Umberto I, Roma, Italy. 10. Radiation Oncology Department, Ospedale Clinicizzato SS. Annunziata, Chieti, Italy. 11. Radiation Oncology Department, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy. 12. Radiation Oncology Department, Centro di Riferimento Oncologico di Aviano, Aviano, Italy. 13. Radiation Oncology Department, Azienda Ospedaliera Sant'Andrea, Roma, Italy.
Abstract
OBJECTIVE: To report the results of a national survey investigating the pattern of practice of curative re-irradiation (ReRT) for recurrent squamous cell carcinoma of the head and neck. METHODS: In March 2016, a 22-item, 4-section questionnaire was sent to all Italian Radiation Oncology centers. Sections were focused on assessing the expertise level of each center and collecting specific information on reRT prescription modalities in the adjuvant and definitive settings. RESULTS: Overall, 77 centers completed the survey. The majority (50/77, 64.9%) of participating radiation oncologists were senior consultants (> 10 years of experience). Of the responding centers, 63 (81.8%) performed curative ReRT, while 14 (18.1%) did not, mainly (5/14, 35.7%) due to the avoidance of severe toxicity. The use of adjuvant ReRT was reported by less than half of the interviewed radiation oncologists (36/77, 46.7%). In case of unresectable local recurrence, definitive ReRT was claimed to be adopted in 55/77 (71.4%) for non-nasopharyngeal and 47/77 (61%) for nasopharyngeal cancer. The preferred treatment technique was Intensity Modulated Radiation Therapy (IMRT) followed by Stereotactic Body Radiation Therapy (SBRT). When IMRT was applied, the most common (19/55 responders, 34.5%) selection of treatment volume consisted of the Gross Tumor Volume (GTV) + 0.5 cm margin to account for microscopic disease. CONCLUSION: Despite the absence of definitive evidence-based recommendations, a possible consideration for ReRT in case of unresectable recurrent head and neck cancer was reported by over 80% of radiation oncologists taking part in the national survey.
OBJECTIVE: To report the results of a national survey investigating the pattern of practice of curative re-irradiation (ReRT) for recurrent squamous cell carcinoma of the head and neck. METHODS: In March 2016, a 22-item, 4-section questionnaire was sent to all Italian Radiation Oncology centers. Sections were focused on assessing the expertise level of each center and collecting specific information on reRT prescription modalities in the adjuvant and definitive settings. RESULTS: Overall, 77 centers completed the survey. The majority (50/77, 64.9%) of participating radiation oncologists were senior consultants (> 10 years of experience). Of the responding centers, 63 (81.8%) performed curative ReRT, while 14 (18.1%) did not, mainly (5/14, 35.7%) due to the avoidance of severe toxicity. The use of adjuvant ReRT was reported by less than half of the interviewed radiation oncologists (36/77, 46.7%). In case of unresectable local recurrence, definitive ReRT was claimed to be adopted in 55/77 (71.4%) for non-nasopharyngeal and 47/77 (61%) for nasopharyngeal cancer. The preferred treatment technique was Intensity Modulated Radiation Therapy (IMRT) followed by Stereotactic Body Radiation Therapy (SBRT). When IMRT was applied, the most common (19/55 responders, 34.5%) selection of treatment volume consisted of the Gross Tumor Volume (GTV) + 0.5 cm margin to account for microscopic disease. CONCLUSION: Despite the absence of definitive evidence-based recommendations, a possible consideration for ReRT in case of unresectable recurrent head and neck cancer was reported by over 80% of radiation oncologists taking part in the national survey.
Entities:
Keywords:
Clinical practice guidelines; Head and Neck Cancer; Radiation therapy; Re-irradiation; Squamous cell carcinoma
Authors: Allen M Chen; D Gregory Farwell; Quang Luu; Suzan Cheng; Paul J Donald; James A Purdy Journal: Int J Radiat Oncol Biol Phys Date: 2010-06-12 Impact factor: 7.038
Authors: Sharon A Spencer; Jonathan Harris; Richard H Wheeler; Mitchell Machtay; Christopher Schultz; William Spanos; Marvin Rotman; Ruby Meredith; Kie-Kian Ang Journal: Head Neck Date: 2008-03 Impact factor: 3.147
Authors: Nadeem Riaz; Julian C Hong; Eric J Sherman; Luc Morris; Matthew Fury; Ian Ganly; Tony J C Wang; Weji Shi; Suzanne L Wolden; Andrew Jackson; Richard J Wong; Zhigang Zhang; Shyam D Rao; Nancy Y Lee Journal: Radiother Oncol Date: 2014-06-30 Impact factor: 6.280
Authors: Corey J Langer; Jonathan Harris; Eric M Horwitz; Nicos Nicolaou; Merrill Kies; Walter Curran; Stuart Wong; Kian Ang Journal: J Clin Oncol Date: 2007-10-20 Impact factor: 44.544
Authors: Eric F Lartigau; Emmanuelle Tresch; Juliette Thariat; Pierre Graff; Bernard Coche-Dequeant; Karen Benezery; Luis Schiappacasse; Marian Degardin; Pierre-Yves Bondiau; Didier Peiffert; Jean-Louis Lefebvre; Thomas Lacornerie; Andrew Kramar Journal: Radiother Oncol Date: 2013-11-18 Impact factor: 6.280
Authors: R De Crevoisier; J Bourhis; C Domenge; P Wibault; S Koscielny; A Lusinchi; G Mamelle; F Janot; M Julieron; A M Leridant; P Marandas; J P Armand; G Schwaab; B Luboinski; F Eschwege Journal: J Clin Oncol Date: 1998-11 Impact factor: 44.544